3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Veronica Wu of First Bight Ventures, BJ Schaknowski of symplr, and Mikyoung Jun of the University of Houston. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know — the first of this new year — I'm introducing you to three local innovators across industries — from health care innovation to energy — recently making headlines in Houston innovation.

Veronica Wu, founder of First Bight Ventures

Veronica Wu, who moved to Houston from Silicon Valley last year, has launched a new venture capital firm to help accelerate synthetic biology startups. Photo courtesy of First Bight Ventures

Veronica Wu is a relative newcomer to Houston. She made the move from Silicon Valley to the Bayou City in the middle of 2021. Wu has announced the launch of First Bight Ventures, a new VC firm focused exclusively on early-stage synthetic biology startups, and based right here in Houston. She plans to leverage the local market to incubate these startups locally, according to the release.

“Houston is well positioned to become a major center for synthetic biology with its existing talent, industries, and capital," she says.

Wu has over 20 years of experience in managerial positions at tech companies like Apple, Tesla, and Motorola, and she served as a founding team member of McKinsey & Company’s Greater China office's business technology practice. Click here to read more.

BJ Schaknowski, CEO of symplr

Houston-based symplr has made another strategic acquisition as it grows its software offerings to its health care clients. Image via symplr.com

Symplr will acquire the Midas platform, which provides users with operations efficiency via data analytics, from New Jersey-based Conduent Incorporated (Nasdaq: CNDT). The deal, valued at $340 million, is expected to close in the first quarter of 2022.

"Midas Health Analytics Solutions brings actionable data and insights to help symplr's health system clients improve patient care and deliver better outcomes," says BJ Schaknowski, CEO of symplr, in a news release. "With integrated quality outcomes and machine learning-based advanced analytics, our combined compliance, quality and safety software portfolio can better predict patient specific risks, deliver population health insights, and proactively improve and support business intelligence performance further advancing symplr's mission of transforming healthcare operations."Click here to read more.

Mikyoung Jun, ConocoPhillips professor of data science at the UH College of Natural Science and Mathematics

A new UH-led program will work with energy corporations to prepare the sector's future workforce. Photo via UH.edu

The Data Science for Energy Transition project, which is funded through 2024 by a $1.49 million grant from the National Science Foundation, includes participation from UH, the University of Houston-Downtown, the University of Houston-Victoria, the University of Houston-Clear Lake, and Sam Houston State University.

At the helm of the initiative is principal investigator Mikyoung Jun, ConocoPhillips professor of data science at the UH College of Natural Science and Mathematics.

“It’s obvious that the Houston area is the capital for the energy field. We are supporting our local industries by presenting talented students from the five sponsoring universities and other Texas state universities with the essential skills to match the growing needs within those data science workforces,” Jun says in the release. “We’re planning all functions in a hybrid format so students located outside of Houston, too, can join in.” Click here to read more.

Houston-based symplr has made another strategic acquisition as it grows its software offerings to its health care clients. Image via symplr.com

Houston health tech company makes $340M deal to acquire analytics biz

m&a moves

A tech-enabled Houston health care operations business has announced another strategic acquisition that would close before the end of the quarter.

Houston-based symplr, which provides software solutions for governance, risk management, and compliance and is backed by California-based Clearlake Capital Group L.P. and Massachusetts-based Charlesbank Capital Partners, announced this week that it will acquire Midas Health Analytics Solutions. Symplr will acquire the Midas platform, which provides users with operations efficiency via data analytics, from New Jersey-based Conduent Incorporated (Nasdaq: CNDT). The deal, valued at $340 million, is expected to close in the first quarter of 2022.

Midas brings to the table a vast data warehouse with over 100 million claims and 30,000 indicators, according to the release, and comparative data from an estimated 800 hospitals.

"As part of our strategy to streamline our portfolio, we consider divestitures of select businesses in order to enhance shareholder and client value." says Cliff Skelton, Conduent president and CEO, in the release. "We believe this is a mutually beneficial transaction and we are focused on providing a seamless transition for our clients. We are committed to delivering robust business process solutions to all industries, including the healthcare industry."

Symplr has been on a bit of a roll when it comes to acquisitions. In March, InnovationMap reported that the SaaS company acquired Phynd Technologies, and symplr went on to acquire another handful of companies throughout 2021. Looking back, symplr has made over a dozen acquisitions and was recognized among the fastest-growing tech companies by Deloitte in 2020.

"The Midas acquisition further strengthens symplr's comprehensive healthcare operations SaaS solutions that enable hospitals and health systems to efficiently navigate the complexities of integrating critical business operations," says Behdad Eghbali, co-founder and managing partner of Clearlake, which acquired symplr in 2018. "We look forward to supporting the company as it continues driving industry consolidation and accelerating organic growth through our O.P.S. value creation framework."

Houston-based symplr has acquired a Dallas SaaS company as it grows its software offerings to its health care clients. Image via symplr.com

Houston health care SaaS company makes strategic acquisition

keep it symplr

A Houston-based health tech company is on an acquisition roll — it's latest deal marks the 11th acquisition in six years.

Software-as-a-service company symplr, which makes health care governance, risk management, and compliance software, has acquired Dallas-based data management SaaS company, Phynd Technologies. Symplr, which is backed by Clearlake Capital Group L.P. and SkyKnight Capital, did not disclose the terms of the transaction.

Symplr's burst of M&A activity spurs from the growing company's mission of providing end-to-end healthcare GRC portfolio, according to a news release. Phynd's platform manages data to provider profiles, locations, clinical expertise, availability, and health plan and network participation.

"Delivering new and significant ongoing value to our customers is integral to symplr's mission. Bringing Phynd into the symplr family helps us further deliver on that promise," says BJ Schaknowski, CEO of symplr, in the news release. "Phynd will integrate with our existing provider software solutions to create an end-to-end provider data management platform for hospitals, health systems, and payers that is unmatched in the healthcare industry today. We're excited to continue leading the healthcare GRC industry with innovative solutions that drive meaningful change."

Phynd was founded in 2012 and raised its $8 million series B in January 2019, according to Crunchbase.

"In the digital healthcare era, organizations must manage their providers and locations as searchable products that are accessible by consumers, referring providers and staff, and care delivery and revenue cycle teams. The combination of symplr and Phynd offers a unique, holistic provider data management offering that includes all providers, locations and virtual visits, helping healthcare organizations become more efficient and competitive," says Tom White, CEO of Phynd, in the release.

"symplr now offers the most robust and scalable central hub of continuously-curated credentialed and referring provider data. We are enthusiastic about executing as one organization and jointly expanding symplr's market leadership," he continues.

The Phynd acquisition is the sixth since symplr formed its partnership with private equity firms Clearlake and SkyKnight in 2018. Based in Santa Monica and Dallas, Clearlake is focused on software solutions across industries and currently has approximately $30 billion of assets under management. San Francisco-based SkyKnight Capital manages over $1.5 billion of PE capital and invests in healthcare, insurance, and business services.

Last year, symplr was named to Deloitte's 26th annual North America Technology Fast 500.The companies on the list were selected based on percentage fiscal year revenue growth from 2016 to 2019. The company came in at No. 426 on the national list with 221 percent growth.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

Startup funding, sportstech win and more trending innovation news for January

INNOVATIONMAP EMAILS ARE AWESOME